Amlodipine plus Metformin

Phase 3Small molecule

Amlodipine plus Metformin is one of 14 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismRecruiting

Primary AldosteronismPhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Primary Aldosteronism

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

6 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 3

Parlodel

VVeroScience

Approved

1 4

Baxfendy

AstraZeneca

Phase 3

1 5

Aldactone

Pfizer

Preclinical

4 6

Amlodipine plus Metformin

TThird Military Medical University

Phase 3

1 7

Adrenocorticotropic Hormone

Astellas

Preclinical

1 8

Intensive BP Control

SSecond Affiliated Hospital of Nanchang University

Preclinical

1 9

Nifedipine ER

MMedical College of Wisconsin

Preclinical

1 10

Mineralocorticoid Receptor Antagonists

UUniversity of Pennsylvania

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Primary Aldosteronism

NCT06523465

Clinical

Trials by Indication[1]

Primary Aldosteronism1 trial

Statin Combined with Amlodipine Treats Primary Aldosteronism

Recruiting·TThird Military Medical University·Phase 4·NCT06523465·180 enrolled

Double-blind1 trial

A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients

Completed·TThird Military Medical University·Phase 4·NCT00538486·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Amlodipine plus Metformin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amlodipine plus Metformin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amlodipine plus Metformin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Military Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThird Military Medical University

Amlodipine plus Metformin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Primary Aldosteronism1 trial

Double-blind1 trial

References

Drug Info

Quick Facts

Related News